prostate

Led VISION, the trial that made lutetium-PSMA the first radioligand therapy for prostate cancer.

Led ARCHES, which established enzalutamide with hormone therapy for metastatic hormone-sensitive prostate cancer.

Led the proton dose-escalation trial in prostate cancer and the comparative-effectiveness debate over proton therapy.

Created the low, intermediate and high-risk classification that every prostate cancer decision starts from.

AR-V7 is a shortened androgen receptor that lacks the part hormone drugs bind, so it stays active without testosterone. Found in circulating tumour cells, it predicts poor response to abiraterone and enzalutamide, but no label uses it yet.

The UCL urologist who has spent her career on the two questions that decide whether a man with prostate cancer is harmed by being diagnosed: who needs a biopsy, and who needs treating at all.

London radiation oncologist who led ALSYMPCA, the trial that showed radium-223 lengthens survival in prostate cancer that has spread to bone, and RADICALS-RT, which showed radiotherapy after prostatectomy can safely wait until the PSA rises.

Led CHAARTED, which showed adding docetaxel to hormone therapy extends survival in newly metastatic prostate cancer.

How much of the DNA floating in a blood sample came from the cancer. Above a few per cent, a plasma test finds what a biopsy would find; below it, a negative result means the test could not see, not that there is nothing there.

Radiation oncologist who built AI models from trial slides to decide which prostate cancer patients need hormone therapy.

British radiation oncologist who led CHHiP, the trial that showed prostate cancer can be treated in 20 radiotherapy sessions rather than 37 with the same results, changing practice worldwide.

Urologist who co-led proPSMA, the trial that showed PSMA PET should replace CT and bone scan for staging prostate cancer.

Urologist who led the CCGA study validating the Galleri methylation-based multi-cancer detection test.

Montreal urologist who led the zoledronic acid trials in prostate cancer bone metastases and was lead author of ARANOTE, which established darolutamide plus hormone therapy for metastatic hormone-sensitive disease.

Led ProtecT, the trial that showed monitoring, surgery and radiotherapy give equally low prostate cancer death rates at 15 years.

London oncologist who helped develop abiraterone and led the STAMPEDE analysis showing that two years of abiraterone alongside hormone therapy and radiotherapy improves survival in high-risk localised prostate cancer.

Led PROMIS, the trial that showed MRI can safely spare a quarter of men from prostate biopsy.

A fault in one of the genes a cell uses to mend broken DNA. It decides whether a PARP inhibitor can be prescribed, but the list of genes that counts is different for each of the four approved routes, and the evidence behind them is mostly evidence about BRCA2.

Led TAX 327, which made docetaxel the first life-extending chemotherapy for prostate cancer, and has spent decades pressing for higher trial standards.

The Bristol social scientist who worked out how to recruit men into a trial that asked them to accept a coin toss between surgery, radiotherapy and doing nothing, and then measured honestly what each did to their lives.

Led TITAN and MAGNITUDE, bringing apalutamide to hormone-sensitive disease and niraparib to HRR-mutant prostate cancer.

Nuclear medicine physician who leads ENZA-p and the PSMA imaging trials shaping Australian theranostics.

Led PROSPER and the PROfound survival analysis, and settled the intermittent hormone therapy question with SWOG 9346.

Urologist behind PROMIS and PRECISION, which put MRI before biopsy in the prostate cancer pathway.

Led ARASENS and SPARTAN, trials that established darolutamide triplet therapy and apalutamide for prostate cancer.

The Royal Marsden oncologist who ran the trial that cut a four-week course of prostate radiotherapy to five treatments, and published the higher urinary side-effect rate alongside the good news.

The British study that measured how bad the standard prostate biopsy really was, and how good a scan could be instead: the evidence that put MRI before the needle in the NHS.

The UK charity that funds prostate cancer research, answers the questions the NHS has no time for through a team of Specialist Nurses, and is paying for half of TRANSFORM, the trial that will decide whether Britain ever screens for this disease.

The Imperial urologist who is research lead on TRANSFORM and joint chief investigator of the trial asking whether taking the lymph nodes out during a prostatectomy does any good.

The oncogeneticist who found most of the common genetic variants that raise a man's risk of prostate cancer, and whose work is the reason the UK's first prostate screening programme is defined by a gene rather than by an age.

Founder and chair of the APCCC consensus conference that guides advanced prostate cancer management worldwide.

The commonest single point mutation in prostate cancer, in about one tumour in eight. Tumours carrying it never have the usual ERG fusion, and men whose metastatic disease carries it tend to stay hormone-sensitive for longer.

Los Angeles urologist who was lead author of EMBARK, the trial that established enzalutamide for men whose prostate cancer is returning fast after surgery or radiotherapy.

The commonest genetic change in prostate cancer, present in roughly half of tumours. Nothing treats it and it does not make the cancer more dangerous; it is useful mainly for recognising that two samples came from the same tumour.

The trial that will decide whether Britain screens for prostate cancer, designed with the screening committee's input and built from the start to answer the question about Black men that every previous trial was too white to answer.